Rationale for the Application of RANKL Inhibition in the Treatment of Langerhans Cell Histiocytosis

Abstract

Langerhans Cell Histiocytosis (LCH) is a rare disease exhibiting both neoplastic and inflammatory features including abundant cytokine secretion both at the lesional and systemic level.